Cancer therapeutics, immuno-oncology, and biotech innovation by Bicara Therapeutics

Bicara Therapeutics Inc. has appointed Chris Sarchi as Chief Commercial Officer as it evolves into a commercial-stage company. Sarchi brings significant experience in guiding oncology businesses ...

Bicara Therapeutics Inc. participated in a Research Breakfast hosted by ACS CAN, underlining its alignment with advocates of evidence-based cancer policy. The company reiterated its dedication ...

Bicara Therapeutics Inc. released three year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab in first line recurrent or metastatic HPV negative head and ...

Bicara Therapeutics Inc. has announced the development of Ficerafusp alfa, the first and only EGFR-directed antibody fused to a TGF-beta ligand trap, engineered for overcoming clinical challenges ...

Bicara Therapeutics Inc. has initiated the FORTIFI clinical trial aimed at addressing a significant unmet medical need in first-line recurrent or metastatic HPV-negative head and neck squamous ...

Bicara Therapeutics Inc. released updated data showing durable responses at three years from its Phase 1/1b study evaluating ficerafusp alfa combined with pembrolizumab as a first line treatment ...

Bicara Therapeutics Inc. released newly published data in the Journal of Clinical Oncology showing clinical outcomes for the combination of ficerafusp alfa and pembrolizumab in first-line ...

Bicara Therapeutics Inc. will release its first quarter 2026 financial results and provide a business update on Monday, May 11. The company will host a conference call at 8:30 AM ET the same ...

Bicara Therapeutics Inc. has launched a Phase 3 clinical trial, selecting a 1500 mg once weekly (QW) dosage for its FORTIFI-HN01 program targeting patients with HPV-negative head and neck squamous ...

Bicara Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results on Monday, March 30, followed by a business update. The company will host a conference call at 8:30 ...

Bicara Therapeutics Inc. reports that HPV negative disease now represents the vast majority of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with a significantly worse ...

Bicara Therapeutics Inc. is advancing research into HPV-negative head and neck squamous cell carcinoma (HNSCC) by combining EGFR and TGF beta blockade to overcome therapeutic resistance. This ...

Bicara Therapeutics Inc. warns that inadequate tumor penetration remains a significant barrier in treating many solid tumors, notably in HPV negative recurrent and metastatic head and neck ...

Bicara Therapeutics Inc has reaffirmed its commitment to supporting patients and caregivers. Nikki Rohan, vice president of global advocacy and community engagement, is recognized for her ...

Bicara Therapeutics Inc. has announced the successful closing of its oversubscribed follow-on equity offering. The proceeds are set to accelerate the development and manufacturing of the ...